The prospective study of the preventive effect of supraorbital transcutaneous stimulation using the Cefaly(R) device against frequent episodic migraine and chronic migraine
- Conditions
- Migraine with and without aura, including chronic migraine (ICHD-3beta 1.1, 1.2.1, or 1.3)
- Registration Number
- JPRN-UMIN000033333
- Lead Sponsor
- Tominaga Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1)The subjects who changed their prophylaxis within the previous 3 months 2)The subjects who received BOTOX or a nerve block within the previous 3 months 3)The subjects with any secondary headache except for MOH 4)The subjects who have severe neurologic and/or psychiatric disorders 5)The subjects who have epilepsy 6)Pregnant or breast-feeding women 7)The subjects who have severe heart, liver, and/or renal dysfunction 8)The subjects who are using opioids 9)The subjects who have allodynia 10)The subjects who have metal and/or electrical device in their body 11)The subjects who are using cardiac pace-maker and/or implantable cardioverter-defibrillator 12)The subjects whom investigators estimate are not eligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The decrease of migraine days after 12 weeks of treatment from run-in phase
- Secondary Outcome Measures
Name Time Method